title: Mesenchymal Stromal Cells as a Therapeutic Strategy to Support Islet Transplantation in Type 1 Diabetes Mellitus.
abstract: Type 1 diabetes is an autoimmune disorder that leads to destruction of pancreatic β islet cells and is a growing global health issue. While insulin replacement remains the standard therapy for type 1 diabetes, exogenous insulin does not mimic the physiology of insulin secretion. Transplantation of pancreatic islets has the potential to cure this disease; however, there are several major limitations to widespread implementation of islet transplants. The use of mesenchymal stromal cells (MSCs) in the treatment of type 1 diabetes has been investigated as an adjunct therapy during islet graft administration to prevent initial islet loss and promote engraftment and revascularization of islets. In this review we will discuss the results of recent MSC studies in animal models of diabetes with a focus on islet transplantation and explore the potential for these findings to be extended to clinical use for the treatment of type 1 diabetes.
authors.affiliation: Athersys, Inc., Department of Regenerative Medicine , Cleveland, OH , USA.
authors.forename: Sarah A
authors.initials: SA
authors.lastname: Busch
authors.affiliation: † ReGenesys, Department of Regenerative Medicine , Leuven , Belgium.
authors.forename: Saskia T J
authors.initials: ST
authors.lastname: van Crutchen
authors.affiliation: Athersys, Inc., Department of Regenerative Medicine , Cleveland, OH , USA.
authors.forename: Robert J
authors.initials: RJ
authors.lastname: Deans
authors.affiliation: Athersys, Inc., Department of Regenerative Medicine , Cleveland, OH , USA.
authors.forename: Anthony E
authors.initials: AE
authors.lastname: Ting
keywords: Bone marrow; Immunomodulation; Islet transplantation; Mesenchymal stromal cell (MSCs); Type 1 diabetes